Chou C.-C.Shen C.-F.Chen S.-J.Chen H.-M.Wang Y.-C.Chang W.-S.Chang Y.-T.Chen W.-Y.Huang C.-Y.Kuo C.-C.Li M.-C.Lin J.-F.Lin S.-P.Ting S.-W.Weng T.-C.Wu P.-S.UN-IN WULin P.-C.Lee S.S.-J.Chen Y.-S.Liu Y.-C.Chuang Y.-C.CHONG-JEN YULI-MIN HUANGLin M.-C.Infectious Diseases Society of TaiwanTaiwan Society of PulmonaryCritical Care Medicine,, Medical Foundation in Memory of Dr. Deh-Lin ChengMedical Foundation in Memory of Dr. Deh-Lin ChengCritical Care MedicineFoundation of Professor Wei-Chuan Hsieh for Infectious Diseases ResearchEducationCY Lee's Research Foundation for Pediatric Infectious DiseasesVaccines,, The 4th Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working groupThe 4th Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working groupVaccines2020-12-242020-12-2420191684-1182https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059437821&doi=10.1016%2fj.jmii.2018.11.004&partnerID=40&md5=a61e8cbc18b7c24f05769ead500d1df6https://scholars.lib.ntu.edu.tw/handle/123456789/532730Pneumonia is a leading cause of death worldwide, ranking third both globally and in Taiwan. This guideline was prepared by the 2017 Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group, formed under the auspices of the Infectious Diseases Society of Taiwan (IDST). A consensus meeting was held jointly by the IDST, Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM), the Medical Foundation in Memory of Dr. Deh-Lin Cheng, the Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education and CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines. The final guideline was endorsed by the IDST and TSPCCM. The major differences between this guideline and the 2007 version include the following: the use of GRADE methodology for the evaluation of available evidence whenever applicable, the specific inclusion of healthcare-associated pneumonia as a category due to the unique medical system in Taiwan and inclusion of recommendations for treatment of pediatric pneumonia. This guideline includes the epidemiology and recommendations of antimicrobial treatment of community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, healthcare-associated pneumonia in adults and pediatric pneumonia. ? 2019[SDGs]SDG3antibiotic agent; antiinfective agent; Acinetobacter; adult; antibiotic resistance; antibiotic therapy; Burkholderia pseudomallei; carbapenem resistance; child; child hospitalization; Chlamydia pneumoniae; chlamydial pneumonia; community acquired pneumonia; comorbidity; disease severity; drug dose escalation; Enterobacteriaceae; epidemiological data; Haemophilus influenzae; health care associated pneumonia; hemodialysis associated pneumonia; hemodynamic parameters; hospital acquired pneumonia; hospital admission; hospital patient; human; infection risk; intensive care unit; Legionella; Letter; medical history; Moraxella catarrhalis; mortality risk; multidrug resistance; Mycoplasma pneumonia; Mycoplasma pneumoniae; nonhuman; nursing home associated pneumonia; outpatient care; pediatric patient; pneumonia; practice guideline; Pseudomonas aeruginosa; Pseudomonas pneumonia; risk factor; staphylococcal pneumonia; Staphylococcus aureus; Streptococcus pneumonia; Streptococcus pneumoniae; Taiwan; time out (healthcare); ventilator associated pneumonia; epidemiology; evidence based medicine; intensive care; organization and management; pneumonia; practice guideline; Adult; Anti-Bacterial Agents; Child; Critical Care; Evidence-Based Medicine; GRADE Approach; Humans; Pneumonia; Taiwanletter10.1016/j.jmii.2018.11.004306129232-s2.0-85059437821